RAPT Therapeutics Inc (FRA:0RA)

€ 1.73 0 (0%) Market Cap: 56.69 Mil Enterprise Value: -32.34 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 41/100

RAPT Therapeutics Inc Corporate Update Call Transcript
Feb 20, 2024
RAPT Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Rapt Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Rapt Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Rapt Therapeutics Inc Annual Shareholders Meeting Transcript
May 24, 2023
Rapt Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Rapt Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Rapt Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Rapt Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Rapt Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) - Presentation Transcript
Sep 12, 2022
Rapt Therapeutics Inc at Wells Fargo Healthcare Conference Transcript
Sep 08, 2022
Rapt Therapeutics Inc at Wells Fargo Virtual Healthcare Conference Transcript
Sep 09, 2021
Rapt Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021

Rapt Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 02:35PM GMT

Release Date Price: €16 (+0.63%)

Transcript

Prakhar Agrawal

Cantor Fitzgerald LP - Analyst

All right, hello, everyone. My name is Prakhar Agrawal. I'm a biotech analyst at Cantor. Welcome to day one of Cantor's Global Healthcare Conference. For our next session, we are very excited to host RAPT Therapeutics. And representing RAPT is Brian Wong, President and CEO.

Brian will be giving a presentation. Brian, take it away.

Brian Wong

RAPT Therapeutics, Inc. - President & CEO

Thanks, Prakhar. And thanks, everyone, for your interest. I'm very pleased today to introduce you to RAPT Therapeutics. We are focused on the discovery and development of novel oral drugs that target critical immune drivers underlying both inflammation and cancer. Our proprietary discovery engine has allowed the acceleration of the discovery of multiple clinically derisked assets that address large market opportunities.

Our lead asset in inflammation is called RPT193. This is a once-daily oral agent that targets inflammatory Th2 cells, which is the same cellular target that's reduced by drugs such as Dupixent.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.